Developer docs
API playgroundTry for free, no card

Search company profiles

InSilicoTrials

Full company profile

uuid00023gx

Namestring
InSilicoTrials
Legal namestring
InSilicoTrials Technologies Ltd
Company typeenum
Private
Founded yearint
2016
Descriptiontext

InSilicoTrials is an Italy-based computational modeling and simulation company that operates a cloud platform for running in silico clinical trials, founded in 2016 and headquartered in Vigevano with an additional presence at Belgium's Health Campus Limburg. The platform combines mechanistic models — including quantitative systems pharmacology (QSP), physiologically-based pharmacokinetic (PBPK), and pharmacokinetic/pharmacodynamic (PKPD) frameworks — with AI-augmented simulation and digital-twin-style patient modeling to help pharmaceutical, biotech, and medical device sponsors de-risk development decisions, optimize trial design, and generate regulatory-acceptable evidence without running full live studies.

The product portfolio spans four primary surfaces. The Scientific Platform houses 500+ validated modeling frameworks across nine therapeutic areas; the Operations Platform handles execution, integration, and workflow management; IRIS is a multi-agent AI orchestration layer that connects models, datasets, and decisions; and MOL2CLIN, launched in partnership with Microsoft Discovery, applies generative AI to move from molecular design through patient-level simulation. The platform is backed by 500M+ patient data points and 50+ peer-reviewed publications, and the company has co-developed "Toward Good Simulation Practice" guidance with the FDA, with the FDA itself having purchased a license to the XPS module. Logo partners include Genentech, Merck, Pfizer, Takeda, Johnson & Johnson, and Sanofi.

Revenue is generated through an enterprise SaaS model with quote-based, multi-year contracts, supplemented by strategic consulting and channel partnerships — notably with Premier Research as a CRO reseller and AVL Partners for distribution. Customer concentration is moderated by both a diversified pharma/biotech/medical device/regulator customer mix and the fact that logo partners may represent pilots rather than full enterprise agreements. Recent strategic activity includes an ARPA-H CARDIOVERSE award of up to $30M (December 2025), Microsoft Discovery integration and MOL2CLIN launch (February 2026), entry into the Microsoft for Startups Pegasus Program (June 2025), and the launch of an AI-Driven Safety Assessment Suite (May 2025).

Short descriptiontext

InSilicoTrials operates a cloud-based in silico clinical trial simulation platform combining 500+ validated mechanistic and AI models across nine therapeutic areas, serving pharmaceutical, biotech, medical device, and regulatory clients to de-risk drug development and accelerate submissions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWilmington, United States
HQ citystring
Wilmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial simulation, computational drug development, in silico modeling, virtual patient populations, pharmacokinetic modeling
Industry3 codes
PRIMARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAG
Clinical Pharmacology & Pharmacometrics (Modeling & Simulation)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Computer Systems Design and Related Services54151
  • Computer Systems Design Services541512
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Computer Integrated Systems Design7373
Product category
Pharmaceutical R&D Simulation Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Software Platform Subscription / SaaS
TypeSubscription Recurring
Description

Enterprise cloud platform access providing computational modeling, simulation, and AI tools for drug development. Accessed via subscription model aligned with FDA and EMA guidelines. Platform includes scientific simulation tools, operations forecasting, IRIS AI orchestration, model libraries, and data libraries.

insilicotrials.com
2Strategic Research & Development Partnerships
TypeProfessional Services
Description

Collaborative projects with pharmaceutical and biotech partners to apply InSilicoTrials' computational modeling to specific drug development programs — e.g., Axoltis Pharma (ALS/neurodegenerative), Telomir Pharmaceuticals, Biofarma Group. Typically structured as fee-for-service or milestone-based engagements.

insilicotrials.com
3Regulatory & Compliance Consulting Services
TypeProfessional Services
Description

AI Compliance Readiness Program — training and consulting to help pharma teams interpret and implement Good AI Practice (GxP-AI) frameworks. Aligns AI systems with FDA/EMA inspection-readiness standards.

insilicotrials.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Personnel
Pricing details1 tier
1Enterprise platform access — full simulation and modeling suite
ModelSubscriptionBilling cadenceAnnual
Notes

No pricing published; enterprise/quote-based. Full platform access including IRIS, 500+ models, virtual populations, simulations, and operations platform.

insilicotrials.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1IRIS
Description

InSilicoTrials Research Intelligent System - multi-agent layer over simulation core that reads protocols, proposes scenarios, runs parallel simulations, and returns optimized trial designs.

insilicotrials.com
+1 more record
Core offering1 text field

InSilicoTrials provides a cloud-based computational modeling and simulation platform that enables drug developers to run in silico clinical trials before initiating human studies. The platform integrates mechanistic models (QSP, PBPK, PK/PD), AI/machine learning, digital twin technology, synthetic data generation, and a multi-agent AI orchestration layer (IRIS) to simulate drug behavior and clinical trial outcomes. It also includes an operations platform for trial planning, cost modeling, scenario forecasting, and resource optimization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Up to 90% efficiency in specific R&D activities through in silico trials
+5 more records
Product overview1 text field

InSilicoTrials offers a unified end-to-end in silico clinical trial platform combining mechanistic models, AI, digital twins, and operational tools. The platform consists of two core products: the Scientific Platform (for clinical trial simulation, virtual patients, and model/data libraries) and the Operations Platform (for trial planning, cost modeling, and resource optimization). Key modules include IRIS for multi-agentic workflow orchestration, a Model Library with 500+ validated QSP/PBPK/PK/PD frameworks, a Data Library covering 500M+ patients, and MOL2CLIN for oncology molecular-to-clinical translation. The platform is aligned with FDA and EMA guidelines and integrates with Microsoft Discovery for enterprise workflows.

Product and service6 records
1Scientific Platform
CategoryCore Platform
Description

Clinical trial simulation platform providing virtual patients, model and data libraries with 500+ validated QSP, PBPK, PK/PD modeling frameworks for drug development. Used by pharmaceutical and biotechnology researchers to simulate trial outcomes before first patient enrollment.

2Operations Platform
CategoryCore Platform
Description

Trial planning, cost modeling, scenario forecasting, and resource optimization platform integrated with the scientific simulation platform in a unified environment. Used by pharma and biotech teams to plan and forecast trial execution.

3IRIS (InSilicoTrials Research Intelligent System)
CategoryAI Orchestration Module
Description

Multi-agentic simulation workflow orchestration system that reads clinical trial protocols, proposes scenarios, runs simulations in parallel, and returns optimized trial designs with evidence trails. Connects every model, dataset, and decision in an intelligent orchestration loop.

4MOL2CLIN
CategoryTherapeutic-Area Module
Description

Enterprise oncology simulation module integrated with Microsoft Discovery. Simulates how a compound behaves in patients by integrating pharmacokinetics, target engagement, tumor growth, safety, and virtual clinical trial outcomes from molecular structure input. Built for oncology drug development teams.

5AI-Driven Safety Assessment Suite
CategorySafety & Toxicology Module
Description

Drug safety assessment suite offering PBPK & QSP models for virtual populations, PK & ADME predictions, blood-brain barrier penetration predictions, ICH-compliant QSAR models for mutagenicity/genotoxicity prediction, and immunogenicity risk screening. Used by pharma R&D teams for preclinical safety evaluation.

6AI Compliance Readiness Program
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership26 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-02
Description

MOL2CLIN module integrated with Microsoft Discovery platform — an enterprise agentic R&D platform combining agentic orchestration, graph-based scientific knowledge, advanced AI reasoning, and Azure HPC for end-to-end oncology drug discovery and development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Leading partner in the CARDIOVERSE initiative ($30M ARPA-H funding), developing virtual heart models for cardiac safety prediction. InSilicoTrials leads the consortium with The Jackson Laboratory as the primary partner, combining computational modeling with genetic and physiological expertise.

3The New York Stem Cell Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Consortium partner in CARDIOVERSE initiative, contributing stem cell expertise to develop physiologically representative virtual heart models for diverse populations.

businesswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Consortium partner in CARDIOVERSE initiative, contributing clinical and biomedical research expertise for virtual heart model development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Consortium partner in CARDIOVERSE initiative, contributing academic research capabilities and clinical expertise for cardiac safety modeling.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-25
Description

AVL Partners extends simulation offering for the healthcare industry through distribution of InSilicoTrials' platform capabilities.

Strategic tierStrategicTypeGTM or Marketing PartnerAnnounced on2025-06-11
Description

InSilicoTrials joins Microsoft for Startups Pegasus Program, accessing enterprise-grade cloud tools (Azure HPC) and go-to-market support to accelerate AI-driven drug development platform adoption.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-12
Description

Expanded platform with advanced predictive models from COSBI. Strategic partnership combining mechanistic modeling and AI-driven simulation to build regulatory-grade computational infrastructure for drug development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-10
Description

SEALS Phase II clinical trial (NX210c for ALS) incorporates InSilicoTrials' virtual patient modeling to create statistical enrichment of the placebo group through in silico patients based on computational methods of historical control data.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-03-07
Description

Collaboration applying cutting-edge AI and simulation technologies to optimize Telomir-1 (telomere-lengthening drug for age-related conditions), improving its safety profile and reducing development costs.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-12-04
Description

MIRA Pharmaceuticals released breakthrough data from AI simulations in collaboration with InSilicoTrials, advancing their drug development program.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-11-13
Description

Collaboration exploring benefits of in silico technology for clinical research. InSilicoTrials analyzed and reinterpreted clinical trial data for Epatrex (NAFLD dietary supplement) using computational modeling.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-08-19
Description

EU Horizon Europe project (€6.7M, 5 years) developing AI and physiology-based mechanical computational models to stratify cancer patients with vertebral metastases at high fracture risk. Coordinated by University of Bologna with 15 partners.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-27
Description

Collaboration to advance therapeutic solutions for neurological disorders (CNS). InSilicoTrials provides computational modeling for NX210c (ALS/Parkinson's drug candidate), including synthetic control arms and disease progression simulation in virtual subjects.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-06-27
Description

Strategic partnership combining COSBI's mechanistic modeling expertise with InSilicoTrials' AI-driven simulation platform to build regulatory-grade computational infrastructure for drug development.

16IBSA Group
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-05-31
Description

Multi-year collaboration integrating AI-driven simulation into IBSA Group's preclinical and clinical development pipelines.

insilicotrials.com
17AchilleS Vaccines
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-04-27
Description

Collaboration combining computational vaccine design with advanced monoclonal antibody modeling tools to tackle infectious diseases with limited therapeutic options.

insilicotrials.com
18Health Campus Limburg
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-03-20
Description

InSilicoTrials established presence at Health Campus in Limburg, Belgium, joining an innovation hub focused on advancing life sciences and digital health in the region.

insilicotrials.com
Strategic tierStrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-03-13
Description

Premier Research embeds InSilicoTrials' platform into its rare-disease CRO offering, providing sponsors with simulation-led regulatory strategy to reduce development timelines.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-12-13
Description

Partnership to accelerate digital transformation for biotech companies, combining laboratory and computational expertise to streamline drug development workflows.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-05-30
Description

Collaboration to digitalize and accelerate pharmaceutical manufacturing process development. RCPE and InSilicoTrials expanded XPS simulation software with new tablet coating simulation module. FDA purchased the XPS license as an in-house simulation tool.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-04-20
Description

Partnership to apply computational simulation to orthopedic medical device development, accelerating regulatory submissions and reducing animal testing requirements.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-21
Description

Takeda, RCPE, InSilicoTrials, and University of Graz partnered to optimize biopharmaceutical manufacturing processes through computational modeling, targeting fill-and-finish process optimization.

24In Silico World Consortium
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-04-16
Description

17-partner EU Horizon 2020 consortium coordinated by University of Bologna (€7.6M funding) developing 11 in silico trials solutions for medical devices, medicinal products, and advanced therapies. InSilicoTrials leads business opportunity analysis and commercial exploitation.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-04-16
Description

EU-funded project developing AI algorithms to predict progression of ALS and Multiple Sclerosis. InSilicoTrials contributes computational modeling and simulation capabilities; organizes iDPP@CLEF open evaluation challenge.

26SimCardioTest (EU Horizon 2020)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-04-16
Description

EU Horizon 2020 project developing in silico trials for cardiovascular diseases, specifically targeting coronary stenosis and cerebral aneurysms.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public biosimulation software company offering PBPK, QSP, PK/PD modeling and regulatory science services to pharma — directly competes with InSilicoTrials' core modeling and simulation stack, but with a much larger installed base and broader regulatory services portfolio.

TypeDirect peer
Description

Provider of PBPK, QSP, and pharmacokinetic modeling software (GastroPlus, MonolixSuite) plus AI-enabled drug discovery tools — competes head-to-head with InSilicoTrials on mechanistic modeling and clinical trial simulation for pharma R&D.

TypeBroad incumbent
Description

Computational chemistry and physics-based simulation platform with a strong life sciences franchise (including a recently launched clinical trial simulation offering) — broader portfolio spanning drug discovery and materials science, with deeper capital and brand.

TypeDirect peer
Description

AI-driven causal simulation platform for clinical trial simulation, synthetic control arms, and precision medicine — directly comparable in silico trials value proposition with focus on oncology and immunology.

TypeEmerging player
Description

AI-native drug discovery company combining high-throughput biology with machine learning — adjacent competitor pursuing in silico approaches to pharma R&D, though primarily asset-focused rather than platform-selling.

TypeEmerging player
Description

AI drug discovery company using generative AI and multi-modal models to identify targets and design molecules — adjacent competitor in computational drug development with a similar name, but focused on proprietary pipeline rather than platform sales.

TypeDirect peer
Description

Physiological modeling and QSP consulting firm serving pharma R&D — smaller, services-led peer with overlapping PBPK/QSP modeling capabilities and similar biotech and pharma customer base.

8Physiomics
TypeDirect peer
Description

UK-based QSP and systems biology consulting firm applying mechanistic modeling to oncology drug development — comparable offering with similar SMB profile and pharma/biotech customer segments.

TypeBroad incumbent
Description

Outcomes research and health economics arm of PPD providing modeling and simulation services including PBPK/QSP — broad incumbent in clinical evidence generation with overlapping pharma customer base.

TypeDirect peer
Description

Quantitative pharmacology services and modeling & simulation software (MonolixSuite reseller historically) — comparable QSP/PK/PD services competitor serving pharma and biotech clients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability12 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InSilicoTrials

Pharmaceutical R&D Simulation Softwareinsilicotrials.com

InSilicoTrials operates a cloud-based in silico clinical trial simulation platform combining 500+ validated mechanistic and AI models across nine therapeutic areas, serving pharmaceutical, biotech, medical device, and regulatory clients to de-risk drug development and accelerate submissions.

What InSilicoTrials does

InSilicoTrials is an Italy-based computational modeling and simulation company that operates a cloud platform for running in silico clinical trials, founded in 2016 and headquartered in Vigevano with an additional presence at Belgium's Health Campus Limburg. The platform combines mechanistic models — including quantitative systems pharmacology (QSP), physiologically-based pharmacokinetic (PBPK), and pharmacokinetic/pharmacodynamic (PKPD) frameworks — with AI-augmented simulation and digital-twin-style patient modeling to help pharmaceutical, biotech, and medical device sponsors de-risk development decisions, optimize trial design, and generate regulatory-acceptable evidence without running full live studies.

The product portfolio spans four primary surfaces. The Scientific Platform houses 500+ validated modeling frameworks across nine therapeutic areas; the Operations Platform handles execution, integration, and workflow management; IRIS is a multi-agent AI orchestration layer that connects models, datasets, and decisions; and MOL2CLIN, launched in partnership with Microsoft Discovery, applies generative AI to move from molecular design through patient-level simulation. The platform is backed by 500M+ patient data points and 50+ peer-reviewed publications, and the company has co-developed "Toward Good Simulation Practice" guidance with the FDA, with the FDA itself having purchased a license to the XPS module. Logo partners include Genentech, Merck, Pfizer, Takeda, Johnson & Johnson, and Sanofi.

Revenue is generated through an enterprise SaaS model with quote-based, multi-year contracts, supplemented by strategic consulting and channel partnerships — notably with Premier Research as a CRO reseller and AVL Partners for distribution. Customer concentration is moderated by both a diversified pharma/biotech/medical device/regulator customer mix and the fact that logo partners may represent pilots rather than full enterprise agreements. Recent strategic activity includes an ARPA-H CARDIOVERSE award of up to $30M (December 2025), Microsoft Discovery integration and MOL2CLIN launch (February 2026), entry into the Microsoft for Startups Pegasus Program (June 2025), and the launch of an AI-Driven Safety Assessment Suite (May 2025).

InSilicoTrials firmographics

Firmographics
Name
InSilicoTrials
Legal name
InSilicoTrials Technologies Ltd
Website
https://insilicotrials.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
InSilicoTrials operates a cloud-based in silico clinical trial simulation platform combining 500+ validated mechanistic and AI models across nine therapeutic areas, serving pharmaceutical, biotech, medical device, and regulatory clients to de-risk drug development and accelerate submissions.
Ownership category
akta.pro rank

InSilicoTrials industry classification

Industry
Product category
Pharmaceutical R&D Simulation Software
NAICS
Computer Systems Design and Related Services (54151), Computer Systems Design Services (541512), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAG
Clinical Pharmacology & Pharmacometrics (Modeling & Simulation)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical trial simulation
  • Computational drug development
  • In silico modeling
  • Virtual patient populations
  • Pharmacokinetic modeling

Where InSilicoTrials is headquartered

Location

Headquarters

HQ city
Wilmington
HQ country
United States
HQ region
North America

Offices4 records

Markets served

InSilicoTrials business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel

Revenue model

  1. Software Platform Subscription / SaaS: Enterprise cloud platform access providing computational modeling, simulation, and AI tools for drug development. Accessed via subscription model aligned with FDA and EMA guidelines. Platform includes scientific simulation tools, operations forecasting, IRIS AI orchestration, model libraries, and data libraries.
  2. Strategic Research & Development Partnerships: Collaborative projects with pharmaceutical and biotech partners to apply InSilicoTrials' computational modeling to specific drug development programs — e.g., Axoltis Pharma (ALS/neurodegenerative), Telomir Pharmaceuticals, Biofarma Group. Typically structured as fee-for-service or milestone-based engagements.
  3. Regulatory & Compliance Consulting Services: AI Compliance Readiness Program — training and consulting to help pharma teams interpret and implement Good AI Practice (GxP-AI) frameworks. Aligns AI systems with FDA/EMA inspection-readiness standards.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise platform access — full simulation and modeling suite

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

InSilicoTrials product offering

Product offering

Core offering

InSilicoTrials provides a cloud-based computational modeling and simulation platform that enables drug developers to run in silico clinical trials before initiating human studies. The platform integrates mechanistic models (QSP, PBPK, PK/PD), AI/machine learning, digital twin technology, synthetic data generation, and a multi-agent AI orchestration layer (IRIS) to simulate drug behavior and clinical trial outcomes. It also includes an operations platform for trial planning, cost modeling, scenario forecasting, and resource optimization.

Product overview

InSilicoTrials offers a unified end-to-end in silico clinical trial platform combining mechanistic models, AI, digital twins, and operational tools. The platform consists of two core products: the Scientific Platform (for clinical trial simulation, virtual patients, and model/data libraries) and the Operations Platform (for trial planning, cost modeling, and resource optimization). Key modules include IRIS for multi-agentic workflow orchestration, a Model Library with 500+ validated QSP/PBPK/PK/PD frameworks, a Data Library covering 500M+ patients, and MOL2CLIN for oncology molecular-to-clinical translation. The platform is aligned with FDA and EMA guidelines and integrates with Microsoft Discovery for enterprise workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • IRIS: InSilicoTrials Research Intelligent System - multi-agent layer over simulation core that reads protocols, proposes scenarios, runs parallel simulations, and returns optimized trial designs.
  • MOL2CLIN

Products and services

  • Scientific Platform Clinical trial simulation platform providing virtual patients, model and data libraries with 500+ validated QSP, PBPK, PK/PD modeling frameworks for drug development. Used by pharmaceutical and biotechnology researchers to simulate trial outcomes before first patient enrollment.
  • Operations Platform Trial planning, cost modeling, scenario forecasting, and resource optimization platform integrated with the scientific simulation platform in a unified environment. Used by pharma and biotech teams to plan and forecast trial execution.
  • IRIS (InSilicoTrials Research Intelligent System) Multi-agentic simulation workflow orchestration system that reads clinical trial protocols, proposes scenarios, runs simulations in parallel, and returns optimized trial designs with evidence trails. Connects every model, dataset, and decision in an intelligent orchestration loop.
  • MOL2CLIN Enterprise oncology simulation module integrated with Microsoft Discovery. Simulates how a compound behaves in patients by integrating pharmacokinetics, target engagement, tumor growth, safety, and virtual clinical trial outcomes from molecular structure input. Built for oncology drug development teams.
  • AI-Driven Safety Assessment Suite Drug safety assessment suite offering PBPK & QSP models for virtual populations, PK & ADME predictions, blood-brain barrier penetration predictions, ICH-compliant QSAR models for mutagenicity/genotoxicity prediction, and immunogenicity risk screening. Used by pharma R&D teams for preclinical safety evaluation.
  • AI Compliance Readiness Program

Quantifiable outcome

  • Up to 90% efficiency in specific R&D activities through in silico trials
  • +5 more outcomes

Companies that use InSilicoTrials

Customer profile

Named customers12 records

Segments5 records

Ideal customer profiles4 records

InSilicoTrials technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability12 records

Feature8 records

InSilicoTrials partnerships and signals

Strategic signal

Partnerships

26 partnerships are on record, tiered core, minor and strategic.

  • Microsoft DiscoverycoreTechnology or Integration · 2 February 2026MOL2CLIN module integrated with Microsoft Discovery platform — an enterprise agentic R&D platform combining agentic orchestration, graph-based scientific knowledge, advanced AI reasoning, and Azure HPC for end-to-end oncology drug discovery and development.
  • The Jackson LaboratorycoreStrategic or Co-development Partner · 22 December 2025Leading partner in the CARDIOVERSE initiative ($30M ARPA-H funding), developing virtual heart models for cardiac safety prediction. InSilicoTrials leads the consortium with The Jackson Laboratory as the primary partner, combining computational modeling with genetic and physiological expertise.
  • The New York Stem Cell FoundationcoreStrategic or Co-development Partner · 22 December 2025Consortium partner in CARDIOVERSE initiative, contributing stem cell expertise to develop physiologically representative virtual heart models for diverse populations.
  • UConn HealthcoreStrategic or Co-development Partner · 22 December 2025Consortium partner in CARDIOVERSE initiative, contributing clinical and biomedical research expertise for virtual heart model development.
  • University of MichigancoreStrategic or Co-development Partner · 22 December 2025Consortium partner in CARDIOVERSE initiative, contributing academic research capabilities and clinical expertise for cardiac safety modeling.
  • AVL PartnersminorChannel Partner/ Reseller/ Distributor · 25 September 2025AVL Partners extends simulation offering for the healthcare industry through distribution of InSilicoTrials' platform capabilities.
  • Microsoft for Startups Pegasus ProgramstrategicGTM or Marketing Partner · 11 June 2025InSilicoTrials joins Microsoft for Startups Pegasus Program, accessing enterprise-grade cloud tools (Azure HPC) and go-to-market support to accelerate AI-driven drug development platform adoption.
  • COSBI (Columbus Open Systems for Biomedical Innovation)coreTechnology or Integration · 12 May 2025Expanded platform with advanced predictive models from COSBI. Strategic partnership combining mechanistic modeling and AI-driven simulation to build regulatory-grade computational infrastructure for drug development.
  • Axoltis PharmacoreStrategic or Co-development Partner · 10 April 2024SEALS Phase II clinical trial (NX210c for ALS) incorporates InSilicoTrials' virtual patient modeling to create statistical enrichment of the placebo group through in silico patients based on computational methods of historical control data.
  • Telomir PharmaceuticalsstrategicStrategic or Co-development Partner · 7 March 2024Collaboration applying cutting-edge AI and simulation technologies to optimize Telomir-1 (telomere-lengthening drug for age-related conditions), improving its safety profile and reducing development costs.
  • MIRA PharmaceuticalsminorStrategic or Co-development Partner · 4 December 2023MIRA Pharmaceuticals released breakthrough data from AI simulations in collaboration with InSilicoTrials, advancing their drug development program.
  • Biofarma GroupminorStrategic or Co-development Partner · 13 November 2023Collaboration exploring benefits of in silico technology for clinical research. InSilicoTrials analyzed and reinterpreted clinical trial data for Epatrex (NAFLD dietary supplement) using computational modeling.
  • METASTRA (EU Horizon Europe)strategicStrategic or Co-development Partner · 19 August 2023EU Horizon Europe project (€6.7M, 5 years) developing AI and physiology-based mechanical computational models to stratify cancer patients with vertebral metastases at high fracture risk. Coordinated by University of Bologna with 15 partners.
  • Axoltis PharmacoreStrategic or Co-development Partner · 27 July 2023Collaboration to advance therapeutic solutions for neurological disorders (CNS). InSilicoTrials provides computational modeling for NX210c (ALS/Parkinson's drug candidate), including synthetic control arms and disease progression simulation in virtual subjects.
  • COSBIcoreTechnology or Integration · 27 June 2023Strategic partnership combining COSBI's mechanistic modeling expertise with InSilicoTrials' AI-driven simulation platform to build regulatory-grade computational infrastructure for drug development.
  • IBSA GroupstrategicStrategic or Co-development Partner · 31 May 2023Multi-year collaboration integrating AI-driven simulation into IBSA Group's preclinical and clinical development pipelines.
  • AchilleS VaccinesstrategicStrategic or Co-development Partner · 27 April 2023Collaboration combining computational vaccine design with advanced monoclonal antibody modeling tools to tackle infectious diseases with limited therapeutic options.
  • Health Campus LimburgminorStrategic or Co-development Partner · 20 March 2023InSilicoTrials established presence at Health Campus in Limburg, Belgium, joining an innovation hub focused on advancing life sciences and digital health in the region.
  • Premier ResearchstrategicChannel Partner/ Reseller/ Distributor · 13 March 2023Premier Research embeds InSilicoTrials' platform into its rare-disease CRO offering, providing sponsors with simulation-led regulatory strategy to reduce development timelines.
  • LSD (Limburgs Stan Dageraad)minorStrategic or Co-development Partner · 13 December 2022Partnership to accelerate digital transformation for biotech companies, combining laboratory and computational expertise to streamline drug development workflows.
  • RCPE (Research Center Pharmaceutical Engineering)coreTechnology or Integration · 30 May 2022Collaboration to digitalize and accelerate pharmaceutical manufacturing process development. RCPE and InSilicoTrials expanded XPS simulation software with new tablet coating simulation module. FDA purchased the XPS license as an in-house simulation tool.
  • MedactaminorStrategic or Co-development Partner · 20 April 2022Partnership to apply computational simulation to orthopedic medical device development, accelerating regulatory submissions and reducing animal testing requirements.
  • TakedacoreStrategic or Co-development Partner · 21 June 2021Takeda, RCPE, InSilicoTrials, and University of Graz partnered to optimize biopharmaceutical manufacturing processes through computational modeling, targeting fill-and-finish process optimization.
  • In Silico World ConsortiumstrategicStrategic or Co-development Partner · 16 April 202117-partner EU Horizon 2020 consortium coordinated by University of Bologna (€7.6M funding) developing 11 in silico trials solutions for medical devices, medicinal products, and advanced therapies. InSilicoTrials leads business opportunity analysis and commercial exploitation.
  • BRAINTEASER (EU Horizon 2020)strategicStrategic or Co-development Partner · 16 April 2021EU-funded project developing AI algorithms to predict progression of ALS and Multiple Sclerosis. InSilicoTrials contributes computational modeling and simulation capabilities; organizes iDPP@CLEF open evaluation challenge.
  • SimCardioTest (EU Horizon 2020)strategicStrategic or Co-development Partner · 16 April 2021EU Horizon 2020 project developing in silico trials for cardiovascular diseases, specifically targeting coronary stenosis and cerebral aneurysms.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

InSilicoTrials competitors and assessment

Company assessment

Direct peers

  • Certara: Public biosimulation software company offering PBPK, QSP, PK/PD modeling and regulatory science services to pharma — directly competes with InSilicoTrials' core modeling and simulation stack, but with a much larger installed base and broader regulatory services portfolio.
  • Simulations Plus: Provider of PBPK, QSP, and pharmacokinetic modeling software (GastroPlus, MonolixSuite) plus AI-enabled drug discovery tools — competes head-to-head with InSilicoTrials on mechanistic modeling and clinical trial simulation for pharma R&D.
  • GNS Healthcare: AI-driven causal simulation platform for clinical trial simulation, synthetic control arms, and precision medicine — directly comparable in silico trials value proposition with focus on oncology and immunology.
  • Rosa & Co. Physiological modeling and QSP consulting firm serving pharma R&D — smaller, services-led peer with overlapping PBPK/QSP modeling capabilities and similar biotech and pharma customer base.
  • Physiomics: UK-based QSP and systems biology consulting firm applying mechanistic modeling to oncology drug development — comparable offering with similar SMB profile and pharma/biotech customer segments.
  • Metrum Research Group: Quantitative pharmacology services and modeling & simulation software (MonolixSuite reseller historically) — comparable QSP/PK/PD services competitor serving pharma and biotech clients.

Broad incumbents

  • Schrödinger: Computational chemistry and physics-based simulation platform with a strong life sciences franchise (including a recently launched clinical trial simulation offering) — broader portfolio spanning drug discovery and materials science, with deeper capital and brand.
  • Evidera (PPD / Thermo Fisher): Outcomes research and health economics arm of PPD providing modeling and simulation services including PBPK/QSP — broad incumbent in clinical evidence generation with overlapping pharma customer base.

Emerging players

  • Recursion: AI-native drug discovery company combining high-throughput biology with machine learning — adjacent competitor pursuing in silico approaches to pharma R&D, though primarily asset-focused rather than platform-selling.
  • Insilico Medicine: AI drug discovery company using generative AI and multi-modal models to identify targets and design molecules — adjacent competitor in computational drug development with a similar name, but focused on proprietary pipeline rather than platform sales.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

InSilicoTrials social profiles

Digital presence

InSilicoTrials compliance and trust

Trust signal

Compliance4 records

InSilicoTrials financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InSilicoTrials leadership team

Management profile

Number of profiles

Profiles11 records

InSilicoTrials funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InSilicoTrials M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InSilicoTrials

What does InSilicoTrials do?

InSilicoTrials provides a cloud-based computational modeling and simulation platform that enables drug developers to run in silico clinical trials before initiating human studies. The platform integrates mechanistic models (QSP, PBPK, PK/PD), AI/machine learning, digital twin technology, synthetic data generation, and a multi-agent AI orchestration layer (IRIS) to simulate drug behavior and clinical trial outcomes. It also includes an operations platform for trial planning, cost modeling, scenario forecasting, and resource optimization.

Is InSilicoTrials a public or private company?

InSilicoTrials is a private company. It is classified as venture growth investor backed and is currently operating.

When was InSilicoTrials founded?

InSilicoTrials was founded in 2016. It employs 11 to 50 people.

Where is InSilicoTrials based?

InSilicoTrials is headquartered in Wilmington, United States, in the North America region.

How does InSilicoTrials make money?

Three revenue lines are on record. Software Platform Subscription / SaaS are the primary driver. The others are strategic Research & Development Partnerships and regulatory & Compliance Consulting Services.

Who are InSilicoTrials's main competitors?

Direct peers on record are Certara, Simulations Plus, GNS Healthcare, Rosa & Co., Physiomics and Metrum Research Group. Broad incumbents are Schrödinger and Evidera (PPD / Thermo Fisher). Emerging players are Recursion and Insilico Medicine.

Does InSilicoTrials have an API?

No public API is recorded for InSilicoTrials.

What industry is InSilicoTrials in?

InSilicoTrials's product category is Pharmaceutical R&D Simulation Software. Its primary akta.pro industry code is HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 54151 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogInSilicoTrials Joins ARPA-H CIRCLE Team to Build a Regulatory-Ready Platform for Critical Illness Digital TwinsInSilicoTrials joined a Sage BioNetworks-led team to build a regulatory-ready platform for testing digital twin models in ARPA-H's CIRCLE program. The platform will automate verification, validation, and uncertainty quantification for digital twins, aiming to make them credible for clinical use in critical care.FinancialContent Business PageInSilicoTrials Joins ARPA-H CIRCLE Team to Build a Regulatory-Ready Platform for Critical Illness Digital TwinsInSilicoTrials joined the ARPA-H CIRCLE team led by Sage BioNetworks to build a regulatory-ready platform for testing digital twin models in critical illness. The platform will automate verification, validation, and uncertainty quantification for AI-driven digital twins. The project is funded by ARPA-H under the CIRCLE initiative.Business Wire BlogInSilicoTrials With The Jackson Laboratory Lead CARDIOVERSE, a $30M Initiative Funded by ARPA-H to Redefine Cardiac Drug Safety with Virtual Heart ModelsInSilicoTrials is leading the CARDIOVERSE consortium alongside The Jackson Laboratory, The New York Stem Cell Foundation, UConn Health, and the University of Michigan in a $30 million initiative funded by ARPA-H's CATALYST program to develop next-generation virtual heart models for cardiac drug safety prediction.PharmiWeb.comInSilicoTrials With The Jackson Laboratory Lead CARDIOVERSE, a $30M Initiative Funded by ARPA-H to Redefine Cardiac Drug Safety with Virtual Heart ModelsInSilicoTrials is leading a consortium including The Jackson Laboratory, The New York Stem Cell Foundation, UConn Health, and the University of Michigan in CARDIOVERSE, a $30 million initiative funded by ARPA-H to develop next-generation virtual heart models for cardiac drug safety testing. The project aims to transform cardiac safety prediction by representing the genetic, physiological, and demographic diversity of the American population, reducing reliance on traditional animal models. CARDIOVERSE is part of ARPA-H's CATALYST program, which seeks to shift early-stage drug safety evaluation toward human-relevant digital systems using computational modeling and AI.citybizInSilicoTrials-Led Consortium Secures Up to $30M ARPA-H Funding for CARDIOVERSEInSilicoTrials is leading a consortium that has secured up to $30 million in funding from ARPA-H for the CARDIOVERSE project, which aims to develop next-generation virtual heart models to improve cardiac safety prediction in drug development. The consortium includes The Jackson Laboratory, The New York Stem Cell Foundation, UConn Health, and the University of Michigan. The initiative is part of ARPA-H's CATALYST program, which seeks to shift early-stage drug safety evaluation away from traditional animal models toward human-relevant digital systems.News-MedicalJAX wins $30 million contract to create computational "digital twins" of the human heartThe Jackson Laboratory (JAX) has secured a $30 million contract from ARPA-H to launch the CARDIOVERSE initiative, which aims to create computational digital twins of the human heart using AI and stem cell data. The project involves partners including the University of Michigan, InSilicoTrials Technologies, and the New York Stem Cell Foundation (NYSCF) to improve drug safety predictions and reduce reliance on large-animal studies.YahooInSilicoTrials Joins Microsoft for Startups Pegasus Program to Accelerate Digital Transformation in HealthcareInSilicoTrials, a health tech company, joined the Microsoft for Startups Pegasus Program, an invitation-only initiative. The company will use Azure's cloud and AI to develop its digital simulation platform for drug development. It will also offer solutions via the Azure Marketplace and pursue co-sell opportunities.Business Wire BlogInSilicoTrials Joins Microsoft for Startups Pegasus Program to Accelerate Digital Transformation in HealthcareInSilicoTrials, a health tech company, joined the Microsoft for Startups Pegasus Program, an invitation-only initiative. The company will use Azure's cloud and AI to develop its digital simulation platform for drug development. It will also offer solutions via the Azure Marketplace and engage in co-sell opportunities.AvlAVL Partners With InSilicoTrials To Extend Simulation Offering For Healthcare IndustryAVL has formed a strategic partnership with InSilicoTrials to integrate AVL FIRE™ M into InSilicoTrials' AI and modeling platform, enhancing simulation tools for the healthcare industry. This collaboration aims to improve product development and operational efficiency by applying advanced computational fluid dynamics in new sectors, particularly pharma and life sciences. The integration of FIRE M and InSilicoTrials' XPS technology enables more accurate predictions and process optimizations in pharmaceutical manufacturing.Engineering.comAVL Partners with InSilicoTrialsAVL and InSilicoTrials have entered a strategic partnership to integrate AVL's computational fluid dynamics software, AVL FIRE M, into InSilicoTrials' AI and modeling platform. This collaboration aims to expand InSilicoTrials' solution offerings by combining CFD with discrete element method simulations for the healthcare and pharmaceutical industries. The exclusive agreement allows InSilicoTrials to market, distribute, and sublicense AVL FIRE M globally.